Current Neurology and Neuroscience Reports

, Volume 8, Issue 5, pp 419–426

Monoclonal antibody treatments for multiple sclerosis



Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. Four MAbs that have been investigated as potential treatments for MS are reviewed in this article. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hemmer B, Hartung HP: Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007, 62:314–326.PubMedCrossRefGoogle Scholar
  2. 2.
    Hawker K: Safe administration and monitoring of monoclonal antibodies in the treatment of multiple sclerosis. Int J Mult Scler Care 2007, 9(Suppl 2):4–21.Google Scholar
  3. 3.
    Buttman P, Reickman P: Treating multiple sclerosis with monoclonal antibodies. Exp Rev Neurotherapeut 2008, 8:433–455.CrossRefGoogle Scholar
  4. 4.
    Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495–497.PubMedCrossRefGoogle Scholar
  5. 5.
    Jones PT, Dear PH, Foote J, et al.: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522–525.PubMedCrossRefGoogle Scholar
  6. 6.
    Queen C, Schneider WP, Selick HE, et al.: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989, 86:10029–10033.PubMedCrossRefGoogle Scholar
  7. 7.
    Rothenberg ME, Klion AD, Roufosse FE, et al.; Mepolizumab HES Study Group: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215–1228.PubMedCrossRefGoogle Scholar
  8. 8.
    Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792.PubMedCrossRefGoogle Scholar
  9. 9.
    Waldmann T, Levy R, Coller B: Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2000, 84:394–406.Google Scholar
  10. 10.
    Morris JC, Waldmann T: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000, 59(Suppl 1):i109–i114.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller DH, Khan OA, Sheremata WA, et al.; International Natalizumab Multiple Sclerosis Trial Group: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Polman CH, O’Connor PW, Havrdova E, et al.: AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899–910.PubMedCrossRefGoogle Scholar
  13. 13.
    Rudick RA, Stuart WH, Calabresi PA, et al.; SENTINEL Investigators: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911–923.PubMedCrossRefGoogle Scholar
  14. 14.
    Traynor K: FDA advisers endorse natalizumab for Crohn’s disease. Am J Health Syst Pharm 2007, 64:1886–1890.PubMedCrossRefGoogle Scholar
  15. 15.
    Yousry TA, Major EO, Ryschkewitsch C, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl Med 2006, 354:924–933.CrossRefGoogle Scholar
  16. 16.
    Stüve O, Marra CM, Cravens PD, et al.: Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007, 64:169–176.PubMedCrossRefGoogle Scholar
  17. 17.
    Bennett JL: Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res 2006, 28:291–298.PubMedCrossRefGoogle Scholar
  18. 18.
    Mullen J, Vartanian T, Adkins M: Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008, 358:647–648.PubMedCrossRefGoogle Scholar
  19. 19.
    Calabresi PA, Giovannoni G, Confavreux C, et al.; AFFIRM and SENTINEL Investigators: The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007, 69:1391–1403.PubMedCrossRefGoogle Scholar
  20. 20.
    Foley JF: Natalizumab discontinuation predisposes to serious infusion related reactions and antibody formation. Mult Scler 2007, 13:1205–1244.CrossRefGoogle Scholar
  21. 21.
    Balcer LJ, Galetta SL, Calabresi PA, et al.: Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007, 68:1299–1304.PubMedCrossRefGoogle Scholar
  22. 22.
    Panzara MA; AFFIRM and SENTINEL Investigators: Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007, 62:335–346.PubMedCrossRefGoogle Scholar
  23. 23.
    Rudick RA, Miller D, Hass S, et al.; AFFIRM Investigators: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007, 68:1390–1401.PubMedCrossRefGoogle Scholar
  24. 24.
    Miller DH, Soon D, Fernando KT, et al.; AFFIRM Investigators: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007, 68:1390–1401.PubMedCrossRefGoogle Scholar
  25. 25.
    Paolillo A, Coles AJ, Molyneux PD, et al.: Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1996, 53:751–757Google Scholar
  26. 26.
    Moreau T, Coles A, Wing M, et al.: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996, 119:225–237.PubMedCrossRefGoogle Scholar
  27. 27.
    Moreau T, Coles A, Wing M, et al.: CAMPATH-IH in multiple sclerosis. Mult Scler 1996, 1:357–365.PubMedGoogle Scholar
  28. 28.
    Coles AJ, Wing MG, Molyneux P, et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296–304.PubMedCrossRefGoogle Scholar
  29. 29.
    Coles AJ, Wing M, Smith S, et al.: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354:1691–1695.PubMedCrossRefGoogle Scholar
  30. 30.
    Loh Y, Oyama Y, Statkute L, et al.: Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007, 109:2643–2548.PubMedCrossRefGoogle Scholar
  31. 31.
    Coles A, for Group TCIS: Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta-1a. Paper presented at 23rd Congress of European Committee for the Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, October 11–14, 2007.Google Scholar
  32. 32.
    Arkfeld DG: The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008 28:205–215.PubMedCrossRefGoogle Scholar
  33. 33.
    Rastetter W, Molina A, White CA: Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004, 55:477–503.PubMedCrossRefGoogle Scholar
  34. 34.
    Cross AH, Stark JL, Lauber J, et al.: Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006, 180:63–70.PubMedCrossRefGoogle Scholar
  35. 35.
    Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A: Rituximab in a patient with multiple sclerosis—effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008, 117:399–403.PubMedCrossRefGoogle Scholar
  36. 36.
    Stüve O, Cepok S, Elias B, et al.: Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005, 62:1620–1623.PubMedCrossRefGoogle Scholar
  37. 37.
    Monson NL, Cravens PD, Frohman EM, et al.: Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005, 62:258–264.PubMedCrossRefGoogle Scholar
  38. 38.
    Hauser SL, Waubant E, Arnold DL, et al.; HERMES Trial Group: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676–688.PubMedCrossRefGoogle Scholar
  39. 39.
    McFarland HF: The B cell—old player, new position on the team. N Engl J Med 2008, 358:664–665.PubMedCrossRefGoogle Scholar
  40. 40.
    Wingerchuk DM, Weinshenker BF: Neuromyelitis optica. Curr Treat Options Neurol 2008, 10:55–66.PubMedCrossRefGoogle Scholar
  41. 41.
    Cree BA, Lamb S, Morgan K, et al.: An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270–1272.PubMedGoogle Scholar
  42. 42.
    Wingerchuk DM, Weinshenker BF: Neuromyelitis optica. Curr Treat Options Neurol 2005, 7:173–182.PubMedCrossRefGoogle Scholar
  43. 43.
    Bielekova B, Richert N, Howard T, et al.: Regulatory CD56 (bright) natural killer cells mediate effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:5941–5946.PubMedCrossRefGoogle Scholar
  44. 44.
    Snyder JT, Shen J, Azmi H, et al.: Direct inhibition of CD40L expression contributes to clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007, 109:5399–5406.PubMedCrossRefGoogle Scholar
  45. 45.
    Vincenti F, Kirkman R, Light S, et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998, 338:161–165.PubMedCrossRefGoogle Scholar
  46. 46.
    Nussenblatt RB, Fortin E, Schiffman R, et al.: Treatment of noninfectious intermediate and posterior uveitis with humanized anti-TAC mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999, 96:7462–7466.PubMedCrossRefGoogle Scholar
  47. 47.
    Nussenblatt RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatment for noninfectious uveits: a multicenter noncomparative interventional case series. Ophthalmology 2005, 112:764–770.PubMedCrossRefGoogle Scholar
  48. 48.
    Bielekova B, Richert N, Howard T, et al.: Humanized anti-CD25 (Daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci 2004, 101:8705–8708.PubMedCrossRefGoogle Scholar
  49. 49.
    Rose J, Watt H, White A, Carlson N: Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004, 56:864–867.PubMedCrossRefGoogle Scholar
  50. 50.
    Rose J, Burns JB, Bjorklund J, et al.: Daclizumab phase II trial in relapsing remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69:785–789.PubMedCrossRefGoogle Scholar
  51. 51.
    Kaufman M, Wynn D, Montalban X, et al.: A phase 2 randomized double-blinded, placebo-controlled multicenter study of subcutaneous daclizumab, a humanized anti-CD-25 monoclonal antibody, in patients with active, relapsing forms of multiple sclerosis—week 44 results. Neurology 2008, 1(Suppl):A220.Google Scholar
  52. 52.
    DiPiro JT, Stamford CT, Schlesselman LS: Allergic and pseudoallergic drug reactions. In Pharmacotherapy: A Pathophysiologic Approach, edn 3. Edited by DiPiro JT, Talbert RL, Yee GC, et al.: Stamford, CT: Appleton and Lange; 1999:1393–1405.Google Scholar
  53. 53.
    Barone MA, ed: The Harriet Lane Handbook, edn 14. St. Louis, MO: Mosby Year Book; 1996:8.Google Scholar
  54. 54.
    Beckwith C, Hermes ER, Najari Z: Latex hypersensitivity. Adverse Drug Reaction News 1994, 7:1–4.Google Scholar
  55. 55.
    Pittman A, Castro M: Allergy and immunology: anaphylaxis. In The Washington Manual of Medical Therapeutics, edn 30. Edited by Ahya SN, Flood K, Paranjothi S. Philadelphia: Lippincott Williams & Wilkins; 2001:243–245.Google Scholar
  56. 56.
    Kappos L, Bates D, Hartung HP, et al.: Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007, 6:431–441.PubMedCrossRefGoogle Scholar
  57. 57.
    Khatri B, Milwaukee WI, Fox R, et al.: Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: results of the natalizumab PLEX study. Neurology 2008, 70(Suppl 1):A227–A228.Google Scholar
  58. 58.
    Steinman L, Zamvil SS: How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006, 60:12–21.PubMedCrossRefGoogle Scholar
  59. 59.
    Rose J, Lorberboum-Galski H, Fitzgerald D, et al.: Chimeric cytotoxin IL2-PE40 inhibits EAE in the adoptive transfer model. J Neuroimmunology 1991, 32:209–217.CrossRefGoogle Scholar
  60. 60.
    Hayosh N, Swanborg R: Autoimmune effector cells: IX Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors. J Immunol 1987, 138:3771–3775.PubMedGoogle Scholar
  61. 61.
    Engelhardt B, Diamanstein T, Wekerle H: Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J Autoimmun 1989, 2:61–73.PubMedCrossRefGoogle Scholar
  62. 62.
    Hafler D, Comston A, Sawcer S, et al.: Risk alleles for multiple sclerosis identified by a genomic study. N Engl J Med 2007, 357:851–862.PubMedCrossRefGoogle Scholar
  63. 63.
    Yednock T, Cannon C, Fritz L, et al.: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63–66.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Neurovirology Research Laboratory, VA Salt Lake City Health Care System; Department of NeurologyUniversity of Utah Neurovirology Research LaboratorySalt Lake CityUSA

Personalised recommendations